Long-term efficacy/safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a phase III trial.
Marco GattornoLaura ObiciInmaculada Calvo PenadésTilmann KallinichSusanne BenselerElise DekkerJérémy LévyFabrizio De BenedettiHelen LachmannPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Control of disease activity, with low flare incidence, was maintained with long-term canakinumab treatment in patients with TRAPS during the 72-week final Epoch of the CLUSTER study, with no new safety findings. This article is protected by copyright. All rights reserved.
Keyphrases
- phase iii
- disease activity
- rheumatoid arthritis
- open label
- systemic lupus erythematosus
- clinical trial
- placebo controlled
- rheumatoid arthritis patients
- phase ii
- ankylosing spondylitis
- double blind
- juvenile idiopathic arthritis
- study protocol
- randomized controlled trial
- risk factors
- combination therapy
- binding protein
- smoking cessation